1. On May 22, 2019, the Defendant revoked the decision not to grant medical care benefits granted to the Plaintiff.

2. The costs of lawsuit shall be.

1. The reasons for the decision on non-approval of the medical care benefit. ① The Plaintiff (the Plaintiff’s life, from January 8, 2019 to January 8, 201) entered the company as at the time of the disaster (the trade name of DLLC) around October 2005, and the confirmation document directly prepared by the Plaintiff around July 2016 is written in July 2017. However, the medical record of the E Mental Health Department stated that the Plaintiff was stating that “the Plaintiff moved to the department of the latest production process from the purchase” at the time of medical treatment on July 7, 2016, the time is recognized as around July 2016.

As the deputy head of the Ansan Factory Production Team, the general department of assembly and production management were in charge of the division.

② On July 29, 2018, on the road, around 13:12, the Plaintiff: (a) went to an emergency room of E hospital because the Plaintiff was out of the power to sit on the left side and on the bridge; (b) was under the diagnosis of brain shield; (c) was transferred to F hospital on July 30, 2018; and (d) was subject to the examination of brain tension with the upper right-hand tension (hereinafter “the instant disaster”). (c) The Plaintiff applied for the medical treatment of the Plaintiff and the Defendant for the medical treatment of the instant case on the ground that it was difficult to recognize the relationship between the Plaintiff and the Defendant on the ground that the Plaintiff’s medical treatment of the instant disease was diagnosed (hereinafter “the instant disease”).

Examining the considerable causal relationship with the instant injury branch, the occurrence of a sudden and difficult incident related to the Plaintiff within 24 hours prior to the occurrence of symptoms and the rapid change in the work environment is not confirmed, and the work hours within one week prior to the occurrence of symptoms exceed 30% of the average weekly period between the 12 weeks prior to the occurrence of symptoms (excluding one week prior to the occurrence).